Objective: To evaluate novel sealing techniques for their biocompatibility and sealing capacity of iatrogenic fetal membrane defects in a pregnant rabbit model.
| INTRODUCTION
Fetal membrane rupture remains the Achilles heel of fetal surgery, occurring in around 28% of laser interventions for twin-twin transfusion syndrome and around 47% of fetoscopic endoluminal tracheal occlusion for congenital diaphragmatic hernia. 1, 2 Therefore, several strategies to either treat or prevent membrane rupture have been proposed. [3] [4] [5] [6] Primary prevention of preterm premature rupture of membranes at the time of fetal surgery would be a useful approach. To our knowledge, only collagen and gelatin plugs have been used clinically for this purpose, however with contradicting results. [7] [8] [9] Clinical studies on potential new solutions are difficult to perform as "first-in-man" studies in pregnancy are challenging, using products that are or would be used off label. It is important to analyze the healing site histologically and to set up a controlled study that is adequately powered. In vivo animal studies are hence vital to allow researchers to explore new solutions. The optimal candidate surgical solution to us should ideally have the following features: (1) The device or material should be readily available; (2) the device or material should be clinically applicable through a 10 Fr, preferentially also an 8 Fr cannula, either as is or after modification; (3) the material should have the ability to be bioactivated; and (4) the material should have the ability to function as a transport of molecular therapeutics to interfere with, apart from the defect, other potential biomolecular mechanism behind iatrogenic preterm premature rupture of membranes. 10 Herein, we report on 4 novel sealant techniques, which we compared to the conventional collagen plugs (Lyostypt) as a reference sealant in the study. One sealant is a condensed collagen, which has been tissue engineered from human fetal membranes and which demonstrated good growth support of amnion epithelial cells. 11 The second sealant is an off-the-shelf collagen (Lyostypt) imbued with fibrinogen. This was tested before in vitro in human amniotic membranes and showed improved sealing capabilities. 12 The third sealant is Tissuepatch, which is a thin film and clinically is used to obtain an airtight sealant in thoracoscopic surgeries. The fourth sealant is Duraseal, which is used in neurosurgery for sealing dura mater defects and preventing cerebrospinal fluid leakage. 13 We tested those sealants in vivo for their biocompatibility (safety) and their efficacy to seal a fetal membrane defect in a pregnant rabbit model for fetoscopy.
| MATERIAL AND METHODS

| Study design
The study design is shown in Figure S1 . Pregnant rabbits underwent a laparotomy at 23 days of gestation under general anesthesia, and 3 fetuses out of the total litter were operated on and assigned to one The doe was placed in the supine position; the abdomen was shaved and disinfected with povidone iodine (Isobetadine; Asta Medica, Brussels, Belgium) and covered with sterile drapes. After midline laparotomy, the uterus was exposed and the fetal sacs counted. We operated on 3 fetuses in each litter, ie, both ovarian end fetuses and one more in the horn with the highest number of fetuses, leaving one unoperated fetus in between. In case of equal numbers of fetuses in both horns, a random side was chosen. First, a small myometrial incision of 3 to 4 mm was made on the antimesometrial side. Blunt dissection of the chorion was performed to gain access to the amnion and to avoid damage to the vitelline vessels ( Figure 1A ). After exposure of the amniotic membrane, it was punctured with a 14G cannula (Braun Medical N.V., Diegem, Belgium) at a perpendicular angle, and a standardized diagnostic fetoscopy of fixed duration (2 min) was performed with a 1.0-mm embryoscope (11510A, Karl Storz, Tutlingen, Germany) within a 1.3-mm examination sheath (11510KA, Karl Storz) (Video S1; Figure 1B ), as previously described.
| Animal and surgical protocols
14 By using this type of diameter instruments, the defect was large enough (around 1.3 mm) to surgically introduce the sealant.
The gestational sacs were randomly assigned to one of the follow- What's already known about this topic?
• Iatrogenic PPROM is a major risk factor of fetoscopic procedures.
• So far, used sealants are not efficient to prevent iPPROM.
• Further research is needed.
What does this study add?
• We screened 5 sealants for biocompatibility and efficacy to seal fetal membrane defects.
• Tissuepatch was biocompatible and had a good efficacy.
• Roussel Hoechst, Brussels, Belgium), and samples were obtained.
| Harvesting and sample preparation
We identified the entry point to the fetal sac by the marking suture and pre-elevated it "en bloc" (amnion, chorion, and myometrium; further referred to as FM sample). Persistence or absence of the plug in the myometrium and/or the fetal membranes was macroscopically assessed from the inside of the amniotic cavity. FM samples of surviving fetuses were stored in tissue embedding cassettes (Simport, Beloeil, Quebec, Canada) on foam biopsy pads (Leica Biosystems N.
V., Maarn, The Netherlands) and submerged in 4% buffered paraformaldehyde (Klinipath BV, Duiven, The Netherlands) for 24 hours. They were then transferred to 70% ethanol and embedded in paraffin. At necropsy, the fetus and its lungs were weighed and the LBWR was calculated.
| Histology and semiautomatic quantification
Paraffin blocks were cut in 4-μm sections displaying the area of the defect. Staining with hematoxylin and eosin was performed, and an average score from 3 high power fields per slide (×40 magnification)
around the defect was calculated for polymorphonuclear cell (PMN) infiltration as previously described. 15 Immunohistochemistry (IHC) for Ki67, vimentin, and cytokeratin was performed according to standard IHC protocols as described before. 16 
| Statistics
Statistical analysis was performed with SPSS Statistics software v21.0.
(IBM, Company ; we calculated that a sample size of 9
fetuses/group would provide a power of ≥85% with a 5% 2-sided type I error to detect a 20% difference in fetal survival. Overall, fetal survival in unsealed sacs tended to be lower (75%) than in unmanipulated control sacs (91%), yet that did not reach statistical significance (χ 2 1 = 3.478; P = .082, Table 1 ). Two sealants had no effect on fetal survival when compared to unmanipulated control sacs: condensed collagen (11/14, 78%; χ 2 1 = 1.831; P = .175) and Tissuepatch (10/13, 77%; χ 2 1 = 2.225; P = .149). Sealing with 3 of the used strategies was associated with a reduced fetal survival compared to negative controls, ie, Lyostypt (13/18, 72%; χ Table 1 ).
Pregnancies sealed using condensed collagen and Tissuepatch underwent further efficacy testing. Tissuepatch sealed sacs had a DVP comparable to that of normal controls (4.64 ± 2.24 vs 6.93 ± 3.80), but condensed collagen sealed sacs had a significantly lower DVP at harvesting (1.89 ± 1.30; F = 8.638; P < .001). There was a 10% amniotic fluid leakage rate (n = 1/10) in the Tissuepatch group, which was significantly less than the condensed collagen group (n = 6/11) and the positive controls (n = 6/12; χ 2 1 = 4.023; P = .045). It was also easier to insert Tissuepatch than the condensed collagen plug with less problems at plug insertion ( χ 2 12 = 179.535; P < .001). There was no difference in macroscopic persistence of the sealing materials used ( χ 2 1 = 11.399; P = .449). Remarkably, there were no differences in LBWR between any of the 4 groups (F = 1.417; P = .213). The degree of cell proliferation (Ki67) was higher in the Tissuepatch group than in negative controls (3.03 ± 1.81 versus 1.23 ± 0.72; F = 4.575; P < .001).
There was no difference in the proportion of cells staining for vimentin or cytokeratin (EMT) between the treatment groups and positive or negative controls (F = 1.804; P = .106) ( Figure 3 and Table 1 ). Single electron microscopy images were taken from the Lyostypt and condensed collagen plugs to compare the structure of the 2 sealants and revealed a smaller diameter, higher density, and better alignment of collagen fibers in the condensed collagen ( Figure S2 ).
| DISCUSSION
Herein, we compared 4 new techniques to seal iatrogenic fetal membrane defects in a fetoscopy rabbit model in terms of biocompatibility and efficacy with a previously used technique of Lyostypt. Three of the sealants were associated with a higher rate of fetal demise compared to nonoperated control pregnancies. Tissuepatch and condensed collagen were the only sealants that had similar results to nonoperated controls in the primary outcome variable of fetal survival, but Tissuepatch proved easier to manipulate surgically and induced limited cell proliferation.
We first screened candidate sealants for the most direct adverse effect, ie, fetal death. In the group of products initially screened yet later disqualified, the fetal death rate ranged from 28% to 52% versus a death rate of around 25% in positive controls. The latter loss rate is in line with previous studies, confirming reproducibility of the model. 4, 16 At the same time, it indicates a frailty of the model due to anesthesia and manipulation of the uterus and its contents. The increased death rate in 3 of the sealant treatment groups would therefore suggest an additional factor besides fetoscopy as potential cause of death. Histological examination did not demonstrate any increased apoptosis or infiltration of PMN in the membranes of these 3 sealant groups. With Abbreviations: DVP, deepest vertical pocket; LBWR, lung-to-bodyweight ratio; PMN, polymorphonuclear cell infiltration.
Results are presented as percentages or as mean with standard deviation (SD) where appropriate. P values were calculated by cross-tables including all groups.
Results that are significantly different from the reference group are marked with an asterisk.
the current design, we were unable to investigate precisely the cause and timing of fetal death, as there was only one time point of fetal viability evaluation, to limit repeated anesthesia in the does. In the collagen + fibrinogen group, there was a higher (>50%) death rate, yet no obvious factor explaining that excess could be identified. Potential explanations are local fibrin formation, when fibrinogen gets in contact with the amniotic fluid. Such increased mortality was already described in earlier experiments, where fibrin glue was used. 17 The exact mechanism behind that remains unclear. The fetal survival in the Duraseal group was also lower. Again, we did not find a direct explanation on necropsy or histology in that group. Potentially, it ties to the injectable nature of the product or its expanding nature. 18 During injection, components of the glue can freely and excessively enter the amniotic cavity and may have direct effects on the fetus.
We then moved into further experimentation with Tissuepatch and condensed collagen, to study efficacy. Condensed collagen plug created unfortunate problems at surgical plug insertion despite its good biocompatibility. Problems associated with insertion of the FIGURE 2 Results of TUNEL staining displayed along with 2 microscopic images of TUNEL stainings at ×40 magnification. DAPI was used as background staining (blue) FIGURE 3 Graphical results of the efficacy testing. Results of the second part of the study that were retrieved as percentage are displayed in Table 1 . DVP, deepest vertical pocket; EMT, epithelial-mesenchymal transition; LBWR, lung-to-bodyweight ratio condensed collagen plug included structural break down of the plug during surgical manipulation and difficulties at suturing, which handling properties and later efficacy. So it is possible that we underestimate efficacy of certain methods because they are difficult to insert in a rabbit. As the application technique itself was not a focus of our study, one would need to investigate products in another model that is better simulating clinical circumstances. The choice for some readouts may also need to be questioned. For instance, we assessed EMT, because it was earlier named to be relevant in human amnion samples from clinical fetoscopies. 20 Epithelial-mesenchymal transition is a key component of wound healing, and we speculated that it would point to local regeneration. Herein, we could not demonstrate any change in EMT between any of the groups, questioning it as an outcome measure in this model. In retrospect, we could have included other readouts such as fetal systemic inflammation to understand adverse effects more effectively or could have followed up on fetuses postoperatively to determine the GA at intrauterine fetal death. This study also involved several subjective outcome measures. No matter how much we tried to make our readouts as objective as possible, they
are not free of a certain amount of operator bias. Lastly, some of our observations were not in line with other studies using the same model.
For instance, we did not find a decrease of LBWR due to the decreased amniotic fluid. 21 On the other hand, our study had strengths; we observed that many other outcomes were similar to what was demonstrated earlier (survival rate, outcomes in positive and negative controls, and the amniotic fluid). This would suggest that findings in the rabbit model are reproducible. Also, we explored several methods, many of them clinically conceivable. The numbers of animals used are high compared to previous studies, and our study was adequately powered. The microscopic readouts were done semiautomatically.
In summary, this study provides experimental evidence that Tissuepatch has the best combination of biocompatibility, surgical ease, and efficacy in sealing an iatrogenic fetal membrane defect in the pregnant rabbit compared to other sealants. However, the current formulation of Tissuepatch is not easy to insert fetoscopically in an effective way. Therefore, our quest into an effective and clinically usable and approved sealing technique is ongoing.
